AI drug discovery SOM Biotech operates a proprietary AI-based drug discovery platform focused on neurological orphan diseases, presenting opportunities to partner with pharma companies seeking accelerated in silico screening and target identification to de-risk early-stage programs.

Clinical-stage focus As a clinical-stage biopharmaceutical company with a growing strategic advisory board and senior leadership additions, there is potential for investment discussions, licensing deals, or milestone-based collaborations to advance pipeline assets.

Strategic partnerships Past partnerships with universities (Minnesota, Ewha Womans) indicate openness to academic collaborations and licensing out targets; prospective partners could structure co-development or target licensing agreements leveraging SOM’s AI platform.

Geographic footprint Based in Catalonia with a multinational collaboration history, there are opportunities to engage regional access programs, EU-based funding, and manufacturing partnerships to support scale-up or clinical trial operations in Europe.

Leadership expansion Recent hires for CFO and Chief Scientific/Manufacturing leadership suggest readiness for scaled operations and governance, signaling receptive conditions for strategic financing, collaborative projects, or contract manufacturing opportunities.